UCLA Health Jonsson Comprehensive Cancer Center | Strategic Alliance Partners

April 25, 2018

Dennis J. Slamon, MD, PhD, director, Clinical/Translational Research, Revlon/University of California, Los Angeles (UCLA) Women's Cancer Research Program, Jonsson Comprehensive Cancer Center, UCLA, discusses the use of biosimilars in clinical practice.

April 24, 2018

Rena D. Callahan, MD, assistant clinical professor of medicine, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the use of endocrine therapy in patients with estrogen receptor (ER)-positive breast cancer.

September 08, 2017

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the differences between antiangiogenic agents in lung cancer.

September 30, 2016

Denise R. Aberle, MD, professor of Radiology in the School of Medicine, of Bioengineering in the Henry Samueli School of Engineering and Applied Science, UCLA Medical Center, discusses novel approaches to screen patients for lung cancer.

December 16, 2015

Sanaz Memarzadeh, MD, PhD, associate professor of Obstetrics and Gynecology, and the director of the Gynecologic Oncology Discovery Lab at UCLA, discusses her preclinical research on resistant tumor cells in ovarian cancer.

December 07, 2015

Phase Ib/II research has shown promise for adoptive cellular therapy combined with ipilimumab in patients with advanced sarcomas.

November 30, 2015

dward Garon, MD, assistant professor of Medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at University of California, Los Angeles, discusses incorporating immunotherapies into the treatment of patients with lung cancer.

November 12, 2015

International study co-led by Dr. Antoni Ribas finds vemurafenib and cobimetinib extend lives and decrease risk of side effects in men and women with melanoma.

October 28, 2015

Noah Federman, MD, director, Pediatric Bone and Soft Tissue Sarcoma Program, University of California, Los Angeles (UCLA), discusses ongoing research in rare bone and soft tissue sarcoma.

October 13, 2015

Sanaz Memarzadeh, MD, PhD, gynecologic oncology, obstetrics and gynecology, University of California, Los Angeles, discusses recurrence rates in ovarian cancer.

September 21, 2015

Dennis J. Slamon, MD, PhD, discusses the impact of the ADAPT and BOLERO trials and how the increased focus on neoadjuvant therapy with trastuzumab and T-DM1 could transform the treatment of HER2-positive breast cancer.

September 13, 2015

Sanaz Memarzadeh, MD, PhD, discusses a combination regimen of birinapant and carboplatin in patients with high-grade serous ovarian cancers and high levels of cellular inhibitor of apoptosis protein (cIAP) in their CA-125–negative cells.

September 03, 2015

Dennis Slamon, MD, PhD, discusses the inhibition of CDK 4/6 and PD-1, which represent two of the most exciting developments in the field of metastatic breast cancer.

July 30, 2015

OncLive's editorial and marketing groups will spread the news about the center's community outreach and research programs.

July 16, 2015

PIK3CA mutations and low/no expression of PTEN correlated with an extension in progression-free survival for patients with metastatic HER2-positive breast cancer treated with the combination of everolimus, trastuzumab, and paclitaxel.

June 02, 2015

The FDA has assigned a priority review designation to the PD-1 inhibitor pembrolizumab as a treatment for patients with advanced NSCLC across all histologies whose disease has progressed on or after platinum-containing chemotherapy, as well as a targeted agent in EGFR- or ALK-positive patients.

February 19, 2015

Dennis J. Slamon, MD, PhD, has had an immeasurable impact on the treatment of women with breast cancer by developing trastuzumab (Herceptin) and helping to launch the era of targeted therapies. He was honored in the Breast Cancer category with a 2014 Giants of Cancer Careâ„¢ award, a program that the Intellisphere® Oncology Specialty Group launched to honor leaders in the field.

February 10, 2015

Richard Finn, MD, Division of Hematology/Oncology at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses findings from a phase II PALOMA-1/TRIO-18 study that examined palbociclib in combination with letrozole as a first-line treatment with ER-positive, HER2-negative, advanced breast cancer.

February 10, 2015

For further insight on the significance of palbociclib's approval, OncLive sat down with the lead investigator of PALOMA-1, Richard Finn, MD, from the Jonsson Comprehensive Cancer Center at UCLA.

November 20, 2014

Treatment with the antibody-drug conjugate T-DM1 (ado-trastuzumab emtansine; Kadcyla) has demonstrated promising clinical efficacy with lower toxicity across a variety of settings for patients with HER2-positive metastatic breast cancer when compared with standard therapies.